摘要
目的分析理肺化瘀方剂对支气管哮喘患者的疗效及患者血清内免疫球蛋白G(IgG)、免疫球蛋白A(IgA)、免疫球蛋白M(IgM)的变化研究。方法选取2017年8月-2018年6月收治的90例支气管哮喘患者的临床资料进行分析,分为两组。对照组采用常规治疗,观察组在对照组基础上给予理肺化瘀方剂治疗,分析两组患者治疗后的临床疗效。结果观察组总有效率97.78%(44/45)与对照组84.44%(38/45)比较,差异有统计学意义(P<0.05)。两组患者治疗前白三烯D4(LTD4)、环磷酸腺苷(cAMP)、高迁移率族蛋白1(HMGB1)、嗜酸粒细胞阳离子蛋白(ECP)、免疫功能、肺功能水平组间比较,差异不具有统计学意义(P>0.05)。观察组患者治疗后cAMP、IgG、IgA、IgM、最大呼气流量(PEF)、用力吸气肺活量(FVC)、第1秒用力呼气容积(FEV1)水平高于对照组,LTD4、HMGB1、ECP、免疫球蛋白E(IgE)水平低于对照组(P<0.05)。结论理肺化瘀方剂治疗支气管哮喘疗效显著,可降低患者LTD4、HMGB1、ECP水平,提高cAMP水平,改善患者的免疫功能及肺功能。
Objective To analyze the efficacy of Lifei Huayu Prescription in patients with bronchial asthma and the changes of serum IgG, IgA and IgM in patients with bronchial asthma. Methods The clinical data of 90 patients with bronchial asthma from August 2017 to June 2018 was selected for analysis. The patients were divided into two groups. The control group was treated with conventional treatment. The observation group was treated with Lifei Huayu Prescription on the basis of the control group. Results The total effective rate of was observation group 97.78%(44/45) and that of was control group was 84.44%(38/45). The total effective rate of the two groups was compared, and the difference was statistically significant(P<0.05). There was no statistically significant difference in two groups’ leukotriene D4(LTD4),cyclic adenosine phosphate(cAMP),high mobility group protein 1(HMGB1),eosinophilic cationic protein(ECP),immune function and lung function(P>0.05). After treatment, the maximum expiratory flow(PEF),cAMP,IgG, IgA and IgM and the forced expiratory volume(FEV1) level in the first second in the observation group were higher than those in the control group, and levels of LTD4,HMGB1,ECP and IgE were lower than those in the control group(P<0.05). Conclusion Lifei Huayu Prescription has a significant therapeutic effect on bronchial asthma, which can reduce levels of LTD4,HMGB1 and ECP, improve cAMP level, and improve the immune function and lung function of patients.
作者
车源霞
晏晨
王天元
CHE Yuanxia;YAN Chen;WANG Tianyuan(Anshun People*s Hospital,Anshun 561000,Guizhou,China)
出处
《中华中医药学刊》
CAS
北大核心
2020年第3期68-70,共3页
Chinese Archives of Traditional Chinese Medicine
基金
中华医学会临床医学科研专项基金(170605952673)
贵州省科学技术计划(黔科合基础[2016]1002).
关键词
理肺化瘀方剂
支气管哮喘
免疫功能
肺功能
Lifei Huayu Prescription
bronchial asthma
immune function
lung function